Krilogy Financial LLC Intellia Therapeutics, Inc. Transaction History

Krilogy Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 22, 2024	BUY	$20.02 - $27.22 $91,211 - $124,014	4,556 Added 9.09%	54,673 $1.22 Million
Q1 2024 Apr 24, 2024	BUY	$23.82 - $32.8 $657,741 - $905,706	27,613 Added 122.7%	50,117 $1.38 Million
Q4 2023 Jan 26, 2024	BUY	$23.16 - $32.34 $521,192 - $727,779	22,504 New	22,504 $686,000
Q1 2018 May 15, 2018	SELL	$19.43 - $34.95 $3,886 - $6,990	-200 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $3,478 - $6,224	200 New	200 $4,000
Q3 2017 Nov 15, 2017	SELL	$15.16 - $25.75 $4,548 - $7,725	-300 Closed	0 $0
Q2 2017 Aug 15, 2017	BUY	N/A	300	300 $5,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Krilogy Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Krilogy Financial LLC with notifications on news.